On July 24, Moderna, Inc. declined 5.07% in regular trading, trading at approximately $54.22 per share, with turnover of $73.37 million. The sell-off was driven by cautious institutional sentiment ahead of the company's Q2 earnings report scheduled for July 31.

On the news front, market consensus expects Q2 EPS of -$1.97, reflecting continued losses as the company navigates revenue seasonality and elevated R&D spending. FactSet data shows the analyst consensus target price stands at $52.16, below the current trading level. Goldman Sachs maintains a Neutral rating with a $67 target, while Bank of America maintains an Underperform rating with a $38 target, signaling broadly cautious sell-side sentiment.

Analysts have flagged that profit recovery may lag expectations due to inventory and capacity utilization pressures on unit costs, limited expense reduction potential, and uncertainty around new product commercialization timelines. Despite recent positive catalysts including unanimous FDA advisory committee support for its flu vaccine candidate mRNA-1010, near-term earnings visibility remains constrained.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)